ArticleMedicina (Kaunas, Lithuania)2026
Comparison of Neoadjuvant TCHP and ddAC+THP Regimens for Pathologic Complete Response in HER2-Positive Breast Cancer: A Multicenter Real-World Analysis of Systemic Inflammatory Biomarkers.
Gökhan Şahin, Ahmet Kürşad Dişli, Firat Sirvan, Mustafa Murat Mıdık, Nur Evsan Boyraz, Oben Belen, Taha Koray Şahin, Ayşe Nuransoy Cengiz, Fatih Kuş, Sıla Gökdere and 6 more
Abstract readMulticenter StudyComparative Study
In one paragraphArticle in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Gökhan ŞahinDepartment of Medical Oncology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey.ORCID 0000-0003-1478-9383 Ahmet Kürşad DişliDepartment of Medical Oncology, Faculty of Medicine, Erciyes University, 38039 Kayseri, Turkey.
Firat SirvanDepartment of Internal Medicine, Faculty of Medicine, Hacettepe University, 06230 Ankara, Turkey.ORCID 0009-0004-8210-0837 Mustafa Murat MıdıkDepartment of Medical Oncology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey.ORCID 0000-0001-9529-7772 Nur Evsan BoyrazDepartment of Internal Medicine, Faculty of Medicine, Hacettepe University, 06230 Ankara, Turkey.
Oben BelenDepartment of Internal Medicine, Faculty of Medicine, Ege University, 35100 Izmir, Turkey.
Taha Koray ŞahinDepartment of Medical Oncology, Faculty of Medicine, Hacettepe University, 06230 Ankara, Turkey.ORCID 0000-0002-3590-0426 Ayşe Nuransoy CengizDepartment of Medical Oncology, Faculty of Medicine, Erciyes University, 38039 Kayseri, Turkey.ORCID 0000-0001-9133-8602 Fatih KuşDepartment of Medical Oncology, Atatürk Sanatorium Training and Research Hospital, 06290 Ankara, Turkey.ORCID 0000-0003-1650-154X Sıla GökdereDepartment of Medical Oncology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey.ORCID 0000-0002-8868-988X Erdem GökerDepartment of Medical Oncology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey.ORCID 0000-0001-6180-713X Burcu ÇakarDepartment of Medical Oncology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey.
Sercan AksoyDepartment of Medical Oncology, Faculty of Medicine, Hacettepe University, 06230 Ankara, Turkey.ORCID 0000-0003-4984-1049 Mevlüde İnançDepartment of Medical Oncology, Faculty of Medicine, Erciyes University, 38039 Kayseri, Turkey.
Deniz Can GüvenDepartment of Medical Oncology, Faculty of Medicine, Hacettepe University, 06230 Ankara, Turkey.ORCID 0000-0002-6924-9467 Hasan Çağrı YıldırımDepartment of Medical Oncology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey.ORCID 0000-0003-3060-377X Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsNeoadjuvant TherapyAdultAntibodies, Monoclonal, HumanizedBiomarkersCarboplatinCyclophosphamideDocetaxelDoxorubicinErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedPaclitaxelPathologic Complete ResponseAntibodies, Monoclonal, HumanizedBiomarkersCarboplatinCyclophosphamideDocetaxelDoxorubicinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPaclitaxelpertuzumabTrastuzumabddAC+THPdual HER2 blockadeHER2-positive breast cancerinflammatory biomarkersneoadjuvant therapypathologic complete responsereal-world studySIRIsystemic inflammation response indexTCHP
Identifiers
PMID42512912
PMCPMC13414168
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390